Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) news covers developments at a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches and nanotechnology platforms. As a dual-listed issuer on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix regularly publishes updates that are relevant to investors following oncology-focused biotechnology and pharmaceutical preparation manufacturing.
Company news frequently highlights progress in the JNJ-1900 (NBTXR3) clinical program, including updates on the global Phase 3 NANORAY-312 study in locally advanced head and neck squamous cell cancers and Phase 1 and Phase 2 studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Releases may also describe regulatory designations, collaboration milestones with Janssen Pharmaceutica NV, and the transfer of sponsorship and operational control of key trials.
Another recurring theme in Nanobiotix news is the Curadigm Nanoprimer platform. The company reports on new patent applications, preclinical in vivo data, and Chemistry, Manufacturing, and Controls (CMC) activities, as well as material transfer agreements with biotechnology and pharmaceutical partners evaluating Nanoprimer combinations with intravenously administered therapeutics.
Investors can also find announcements related to capital markets activity, such as royalty-based financing agreements with HealthCare Royalty (HCRx), inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, and periodic disclosures on shares outstanding and voting rights under French regulations. In addition, Nanobiotix issues notices about participation in investor and healthcare conferences, where management presents the company’s strategy and clinical pipeline.
By following NBTX news, readers can track clinical, financial, and strategic updates that shape the company’s development trajectory and its work in oncology, drug bioavailability and biodistribution, and central nervous system disorder applications.
On August 31, 2022, Nanobiotix reported a total of 34,875,872 shares outstanding, with voting rights totaling 36,274,272 theoretical rights and 36,250,130 exercisable rights. This announcement aligns with regulations from the French Financial Markets Authority, ensuring transparency in shareholder voting. Nanobiotix focuses on innovative therapeutic approaches for cancer treatment, utilizing its nanoparticle technology, specifically targeting head and neck cancers. Investors can find further details on their official website.
Nanobiotix and LianBio have announced the enrollment of the first patient in the pivotal Phase 3 NANORAY-312 trial for NBTXR3, targeting elderly patients with locally advanced head and neck cancer ineligible for platinum-based chemotherapy. This trial will assess the effectiveness of NBTXR3 combined with radiotherapy and cetuximab. With a global enrollment goal of 500 patients, LianBio aims to enroll approximately 100 in Asia. Previous trials show promising survival rates, positioning NBTXR3 as a potential key treatment in a rapidly growing radiotherapy market in Asia.
Nanobiotix (NASDAQ: NBTX), a late-stage biotechnology company, announced the participation of co-founder Laurent Levy and CFO Bart Van Rhijn at the H.C. Wainwright 24th Annual Global Investment Conference in New York and virtually from September 12-14, 2022.
Their presentation is scheduled for September 12, 2022, at 2:00 PM ET. A live webcast will be available on the company's website, with a replay accessible within 48 hours.
Nanobiotix has announced the total outstanding shares as of July 31, 2022, amounting to 34,875,872. The total number of voting rights is reported as 36,274,272 (theoretical) and 36,299,593 (exercisable). This financial disclosure aligns with the regulatory requirements under French commercial law. The company focuses on innovative treatments through its nanoparticle platform, particularly for solid tumors and head and neck cancers.
NANOBIOTIX (NASDAQ: NBTX) released its Half-Year report on its liquidity contract with Gilbert Dupont. As of June 30, 2022, the liquidity account held 25,706 shares and a cash balance of €60,051.07. In the first half of 2022, the total buy side traded volume reached 306,341 shares, amounting to €1,883,900.28, while the sell side traded volume was 296,091 shares, totaling €1,846,535.38. Comparatively, as of December 31, 2021, the account held 15,456 shares and €97,415.97 in cash. The report complies with AMF Decision N°2021-01 on liquidity contracts.
Nanobiotix, traded on NASDAQ as NBTX, reported its share structure as of June 30, 2022. The total number of outstanding shares is 34,875,872, with 36,329,077 theoretical voting rights and 36,303,371 exercisable voting rights. This data is critical for investors tracking corporate governance and voting processes. Nanobiotix is dedicated to innovative cancer therapies, particularly focusing on head and neck cancers using its proprietary nanoparticle platform.
Nanobiotix (Euronext: NANO, Nasdaq: NBTX) reported its outstanding shares on May 31, 2022, totaling 34,875,872. The total number of gross voting rights reached 36,393,442, while the net voting rights stood at 36,373,830. This update aligns with regulatory requirements set by the French Financial Markets Authority. As a late-stage clinical biotechnology firm, Nanobiotix focuses on developing innovative therapies for solid tumors, particularly in head and neck cancers, utilizing its proprietary nanoparticle platform.
NANOBIOTIX (Nasdaq: NBTX) reported promising results for its radioenhancer NBTXR3 at the 2022 ASCO Annual Meeting. In a phase 1b/2 study involving 12 patients with stage 4 head and neck cancer, NBTXR3 combined with chemoradiation demonstrated a 100% disease control rate and a 58.3% overall response rate. Similarly, in a rectal cancer study of 31 patients, there was a 100% disease control rate, with 96% of patients eligible for R0 surgery. The data supports NBTXR3's potential for improving treatment outcomes across solid tumors.
NANOBIOTIX, a late-stage clinical biotechnology firm, has announced its Annual Combined Shareholders General Meeting set for June 23, 2022, at 9:30 AM CET in Paris. Shareholders can find the meeting's agenda and details published on May 18, 2022, in the Bulletin des Annonces Légales Obligatoires. Additionally, they can access relevant documents on the company's website. The firm is focused on its innovative oncology product, NBTXR3, which shows promise in treating solid tumors using radiotherapy. A financial agenda for updates in September and November has also been outlined.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
